AceView: Gene:MDK, a comprehensive annotation of human, mouse and worm genes with mRNAs or ESTsAceView.

cDNA accession Links to the sequence	Tissue most 5' clones in red	Match mRNA	From bp to bp in mRNA	From bp to bp in accs.	Clone encodes complete protein (with AA variation)	Features	Anomalies detected by AceView	Accession match over (% length)	Base differences relative to genome (% identity)
BU184807	melanotic melanoma, cell line, skin	.a	1 to 505	1 to 505				505/889 (56 %)	13 diff (98.6 %id)
BQ668643	epidermoid carcinoma, cell line, salivary gland	.a	1 to 503	1 to 503				503/926 (54 %)	13 diff (98.6 %id)
BQ668678	epidermoid carcinoma, cell line, salivary gland	.a	1 to 673	1 to 680		tiling clone,		680/963 (70 %)	32 diff (96.7 %id)
AK309963	Prostate	.a	29 to 1885	1 to 1857	exact	tiling clone,		1857/1857 (100 %)	1 diff (100.0 %id)
DC383107	Prostate	.a	29 to 558	1 to 530				530/530 (100 %)	1 diff (99.9 %id)
BI519974	brain, medulla	.a	31 to 766	1 to 747				745/825 (90 %)	12 diff (98.6 %id)
TI_43964004		.a	31 to 766	58 to 804				745/882 (84 %)	16 diff (98.2 %id)
AK308210	small intestine	.a	156 to 1834	1 to 1678	R230A L231C	tiling clone,		1678/1678 (100 %)	1 diff (100.0 %id)
DT220418	brain	.a	156 to 646	1 to 490				490/490 (100 %)	1 diff (99.8 %id)
DC387806	small intestine	.a	156 to 727	1 to 572				572/572 (100 %)	0 diff (100 %id)
CN266396	embryonic stem cells, cell lines H1, H7, andH9	.a	170 to 561	84 to 475				392/475 (82 %)	9 diff (98.2 %id)
CN266436	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.a	186 to 557	1 to 372				372/372 (100 %)	1 diff (99.8 %id)
BM839270	Ascites, stomach	.a	200 to 636	1 to 430				430/430 (100 %)	4 diff (99.1 %id)
CN266404	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.a	205 to 673	1 to 469				469/470 (99 %)	0 diff (100 %id)
BQ653612	hepatocellular carcinoma, cell line, Liver	.a	219 to 673	1 to 455				455/1205 (37 %)	3 diff (99.8 %id)
CN266462	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.a	230 to 820	1 to 591				591/591 (100 %)	0 diff (100 %id)
TI_57197830		.a	305 to 908	32 to 637				606/637 (95 %)	12 diff (98.2 %id)
BI820606	pooled brain, lung, testis	.a	306 to 908	1 to 605				605/605 (100 %)	7 diff (98.9 %id)
CN266424	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.a	310 to 748	1 to 439				439/439 (100 %)	0 diff (100 %id)
AU126711		.a	312 to 788	2 to 481		capped		480/482 (99 %)	5 diff (99.0 %id)
T50637	ovary	.a	335 to 562	1 to 229				229/267 (85 %)	13 diff (95.2 %id)
CN266400	embryonic stem cells, DMSO-treated H9 cellline	.a	408 to 694	1 to 287				287/287 (100 %)	1 diff (99.7 %id)
BP419708	small intestine	.a	415 to 773	1 to 360			Submitted on the opposite strand	360/361 (99 %)	3 diff (99.2 %id)
CN266406	embryonic stem cells, DMSO-treated H9 cellline	.a	422 to 751	4 to 333				330/333 (99 %)	6 diff (98.2 %id)
CN266454	embryonic stem cells, DMSO-treated H9 cellline	.a	429 to 813	1 to 385				385/385 (100 %)	3 diff (99.3 %id)
AA037265	senescent fibroblast	.a	429 to 854	1 to 435				435/460 (94 %)	24 diff (94.8 %id)
AW001140	colon, colonic mucosa from 3 patients with Crohn'sdisease	.a	429 to 803	415 to 41				375/415 (90 %)	8 diff (98.1 %id)
CN266474	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.a	431 to 835	1 to 406				406/407 (99 %)	4 diff (99.1 %id)
W04805	lung	.a	431 to 550	1 to 120				120/120 (100 %)	5 diff (95.9 %id)
BF799202	colon_ins	.a	433 to 747	338 to 24			Submitted on the opposite strand	315/338 (93 %)	2 diff (99.5 %id)
CN266429	embryonic stem cells, DMSO-treated H9 cellline	.a	435 to 755	1 to 321				321/321 (100 %)	0 diff (100 %id)
CN266487	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.a	436 to 770	1 to 335				335/335 (100 %)	0 diff (100 %id)
BM827021	Ascites, stomach	.a	437 to 752	1 to 316				316/316 (100 %)	0 diff (100 %id)
CN266421	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.a	441 to 875	1 to 435				435/435 (100 %)	0 diff (100 %id)
CN266385	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.a	443 to 652	1 to 210				210/210 (100 %)	0 diff (100 %id)
CN266486	embryonic stem cells, DMSO-treated H9 cellline	.a	444 to 748	1 to 305				305/305 (100 %)	1 diff (99.7 %id)
R72795	breast	.a	452 to 674	1 to 220				220/260 (84 %)	17 diff (93.5 %id)
CN266475	embryonic stem cells, DMSO-treated H9 cellline	.a	474 to 861	1 to 389				389/389 (100 %)	1 diff (99.8 %id)
BM760497	lymph node, stomach	.a	506 to 750	1 to 245				245/245 (100 %)	1 diff (99.6 %id)
AA155766	Pancreas	.a	511 to 666	98 to 251				154/251 (61 %)	6 diff (97.7 %id)
AA155768	Pancreas	.a	511 to 666	98 to 251				154/251 (61 %)	6 diff (97.7 %id)
AA444088	ovarian tumor, ovary	.a	532 to 840	1 to 306				306/522 (58 %)	9 diff (98.3 %id)
AA340127	brain	.a	576 to 781	1 to 206				206/206 (100 %)	0 diff (100 %id)
AA095477		.a	674 to 835	1 to 161				161/162 (99 %)	9 diff (94.5 %id)
AA121965	Pancreas	.a	723 to 872	1 to 151				151/151 (100 %)	1 diff (99.4 %id)
CB215466	normal endometrium, late proliferativephase, cycle day 13, uterus	.a	861 to 1511	1 to 650				650/650 (100 %)	1 diff (99.9 %id)
BX349040	Placenta Cot 25-normalized	.a	1051 to 1838	1 to 783				783/849 (92 %)	33 diff (96.2 %id)
DT219727	brain	.a	1057 to 1728	1 to 672				672/672 (100 %)	0 diff (100 %id)
CN266533	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.a	1089 to 1627	19 to 559				541/559 (96 %)	6 diff (99.0 %id)
TI_149292995		.a	1171 to 1886	792 to 82		AAA		711/791 (89 %)	25 diff (96.9 %id)
AA121966	Pancreas	.a	1417 to 1886	470 to 1				470/473 (99 %)	4 diff (99.2 %id)
AI127036	heart	.a	1494 to 1893	400 to 2				399/400 (99 %)	0 diff (100 %id)
AI185816	lung	.a	1494 to 1887	394 to 1				394/394 (100 %)	0 diff (100 %id)
AW474443	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.a	1523 to 1886	364 to 1				364/364 (100 %)	4 diff (99.0 %id)
AA443893	ovarian tumor, ovary	.a	1554 to 1886	356 to 22		AAA		335/528 (63 %)	7 diff (98.7 %id)
AI819736	2 pooled tumors (clear cell type), Kidney	.a	1872 to 2193	1 to 323		tiling clone,	Submitted on the opposite strand	323/323 (100 %)	8 diff (97.6 %id)
AI285914	pooled	.a	1886 to 2265	1 to 380		tiling clone,	Submitted on the opposite strand	380/380 (100 %)	4 diff (99.0 %id)
BM924518	pooled colon, kidney, stomach	.b	1 to 959	1 to 973	F49S S50L R52D P53R G54V ...	tiling clone,		973/1070 (90 %)	32 diff (97.1 %id)
BY796308	eye	.b	8 to 704	1 to 697				697/697 (100 %)	0 diff (100 %id)
BQ647176	hepatocellular carcinoma, cell line, Liver	.b	10 to 748	9 to 753				745/859 (86 %)	13 diff (98.5 %id)
BE563428	adenocarcinoma, Pancreas	.b	52 to 793	1 to 736				736/762 (96 %)	17 diff (97.8 %id)
BQ225536	epithelioid carcinoma, Pancreas	.b	86 to 931	1 to 862				862/865 (99 %)	23 diff (97.4 %id)
CN266490	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.b	94 to 711	1 to 620				620/620 (100 %)	6 diff (99.1 %id)
CN266466	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.b	113 to 682	1 to 571				571/571 (100 %)	2 diff (99.7 %id)
BG622813	placenta	.b	113 to 782	1 to 669				669/687 (97 %)	11 diff (98.4 %id)
CN266369	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.b	126 to 822	1 to 697				697/697 (100 %)	1 diff (99.9 %id)
CN266451	embryonic stem cells, DMSO-treated H9 cellline	.b	127 to 782	1 to 656				656/656 (100 %)	7 diff (99.0 %id)
BQ069753	brain, neuroblastoma, cell line	.b	140 to 963	1 to 823		tiling clone, AAA		823/823 (100 %)	4 diff (99.6 %id)
BQ070699	brain, neuroblastoma, cell line	.b	140 to 966	1 to 848		tiling clone,		848/1076 (78 %)	33 diff (97.0 %id)
BE260964	brain, neuroblastoma	.b	153 to 835	1 to 680				680/680 (100 %)	12 diff (98.3 %id)
BF206407	brain, neuroblastoma	.b	157 to 893	1 to 731				731/984 (74 %)	23 diff (97.7 %id)
CN266438	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.c	1 to 437	1 to 437		tiling clone,		437/437 (100 %)	3 diff (99.4 %id)
BM887813	eye	.c	12 to 528	1 to 520		AAA		520/521 (99 %)	7 diff (98.7 %id)
BI914771	brain	.c	23 to 586	1 to 565		tiling clone,		565/735 (76 %)	6 diff (99.2 %id)
TI_57244108		.c	23 to 586	34 to 598				565/768 (73 %)	12 diff (98.5 %id)
BM546345	ovary (pool of 3)	.c	29 to 559	21 to 551				531/555 (95 %)	13 diff (97.7 %id)
AL553751	placenta, Placenta Cot 25-normalized	.c	36 to 914	1 to 880		tiling clone,		880/880 (100 %)	12 diff (98.7 %id)
CN266456	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.c	37 to 543	1 to 507				507/507 (100 %)	1 diff (99.9 %id)
BI198298	brain, neuroblastoma	.c	39 to 527	1 to 497				497/783 (63 %)	24 diff (97.0 %id)
BM798788	myeloma	.c	39 to 370	1 to 332				332/332 (100 %)	0 diff (100 %id)
BM809472	amelanotic melanoma, cell line, skin	.c	40 to 394	1 to 354				354/1333 (26 %)	10 diff (99.3 %id)
BM826761	stomach	.c	41 to 439	1 to 399				399/399 (100 %)	0 diff (100 %id)
BM852008	stomach	.c	42 to 482	1 to 441				441/441 (100 %)	2 diff (99.6 %id)
DB496226	hypothalamus	.c	43 to 513	1 to 471				471/471 (100 %)	2 diff (99.6 %id)
BM839872	myeloma	.c	43 to 495	10 to 462				453/453 (100 %)	1 diff (99.8 %id)
CN266365	embryonic stem cells, DMSO-treated H9 cellline	.c	47 to 514	1 to 468				468/468 (100 %)	0 diff (100 %id)
CN266389	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.c	47 to 405	1 to 364				362/364 (99 %)	5 diff (98.7 %id)
TI_57177769		.c	48 to 586	28 to 576				549/836 (65 %)	26 diff (96.9 %id)
BI766264	pooled lung and spleen	.c	53 to 586	1 to 544				544/804 (67 %)	24 diff (97.1 %id)
BQ233742	brain	.c	56 to 903	1 to 863		tiling clone,		863/894 (96 %)	33 diff (96.4 %id)
CN266489	embryonic stem cells, cell lines H1, H7, andH9	.c	67 to 548	1 to 483				483/483 (100 %)	6 diff (98.8 %id)
CN266477	embryonic stem cells, DMSO-treated H9 cellline	.c	73 to 559	1 to 487				487/487 (100 %)	3 diff (99.4 %id)
CX760719	Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass	.c	83 to 563	1 to 481			Submitted on the opposite strand	481/706 (68 %)	1 diff (99.9 %id)
CN266356	embryonic stem cells, cell lines H1, H7, andH9	.c	90 to 545	1 to 456				456/456 (100 %)	1 diff (99.8 %id)
CN266376	embryonic stem cells, cell lines H1, H7, andH9	.d	1 to 451	4 to 454		tiling clone,		454/454 (100 %)	2 diff (99.6 %id)
CR590366	neuroblastoma	.d	15 to 1353	1 to 1339	exact	tiling clone,		1339/1339 (100 %)	0 diff (100 %id)
CN266379	embryonic stem cells, DMSO-treated H9 cellline	.d	29 to 454	1 to 426				426/426 (100 %)	2 diff (99.6 %id)
CN266461	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.d	43 to 570	1 to 528				528/528 (100 %)	0 diff (100 %id)
AL516918	brain, neuroblastoma, neuroblastoma cells	.d	53 to 734	35 to 712	D26X D95*	fully sequenced,		678/712 (95 %)	10 diff (98.6 %id)
BF688256	eye, normal pigmented retinal epithelium	.d	649 to 1353	1 to 705				705/825 (85 %)	11 diff (98.7 %id)
AL516917	brain, neuroblastoma, neuroblastoma cells	.d	704 to 1346	638 to 8		fully sequenced,		631/638 (98 %)	3 diff (99.6 %id)
CN278003	embryonic stem cells, DMSO-treated H9 cellline	.e	1 to 540	1 to 540		tiling clone,		540/540 (100 %)	0 diff (100 %id)
N31429	melanocyte	.e	361 to 698	1 to 335		tiling clone,		335/365 (91 %)	18 diff (95.1 %id)
N25317	melanocyte	.e	793 to 865	73 to 1		tiling clone,		73/73 (100 %)	0 diff (100 %id)
BE904189	epithelioid carcinoma, Pancreas	.f	1 to 783	1 to 774	C52G Q104K G105A T106P L107*	tiling clone,		776/857 (90 %)	28 diff (96.8 %id)
CR601916	T cells (Jurkat cell line) Cot10-normalized	.f	10 to 1035	1 to 1026	exact	tiling clone,		1026/1026 (100 %)	0 diff (100 %id)
BX346163		.f	10 to 589	1 to 580		fully sequenced,		580/580 (100 %)	2 diff (99.7 %id)
BU860074	adenocarcinoma, cell line, breast	.f	12 to 628	1 to 621				621/1060 (58 %)	11 diff (99.0 %id)
CN266464	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.f	22 to 558	1 to 537				537/537 (100 %)	1 diff (99.9 %id)
CN266471	embryonic stem cells, cell lines H1, H7, andH9	.f	22 to 280	1 to 259				259/259 (100 %)	0 diff (100 %id)
CN266459	embryonic stem cells, DMSO-treated H9 cellline	.f	23 to 500	1 to 479				479/479 (100 %)	1 diff (99.8 %id)
CN277787	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.f	23 to 344	1 to 322				322/322 (100 %)	0 diff (100 %id)
BQ070751	brain, neuroblastoma, cell line	.f	102 to 727	1 to 627				627/1150 (54 %)	26 diff (97.8 %id)
AU126531		.f	137 to 679	2 to 549		capped		548/548 (100 %)	13 diff (97.7 %id)
BF983613	duodenal adenocarcinoma, cell line, small intestine	.f	190 to 912	1 to 721	K138T K140N K142T D143G			721/1125 (64 %)	25 diff (97.8 %id)
BX346162		.f	528 to 1024	509 to 12		fully sequenced,		498/509 (97 %)	2 diff (99.7 %id)
CN266447	embryonic stem cells, DMSO-treated H9 cellline	.g	1 to 742	1 to 743	exact	tiling clone,		743/743 (100 %)	6 diff (99.2 %id)
NM_001012333.1		.g	6 to 901	1 to 896	exact	RefSeq, AAA		896/896 (100 %)	0 diff (100 %id)
AA428047		.g	9 to 470	1 to 457		fully sequenced,		457/457 (100 %)	10 diff (97.9 %id)
BM016739	astrocytoma grade IV, cell line, brain	.g	19 to 732	1 to 714	K108N K109E A110G R111A Y112L ...			714/717 (99 %)	14 diff (98.1 %id)
TI_59386973		.g	20 to 732	99 to 811	K108N K109E A110G R111A Y112L ...			713/716 (99 %)	13 diff (98.2 %id)
CN266346	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.g	43 to 720	1 to 677	exact			677/677 (100 %)	3 diff (99.6 %id)
CN266411	embryonic stem cells, cell lines H1, H7, andH9	.g	94 to 778	1 to 686	exact	tiling clone,		686/686 (100 %)	3 diff (99.6 %id)
AA427949		.g	440 to 878	442 to 5		tiling clone, fully sequenced,		438/442 (99 %)	0 diff (100 %id)
NM_002391.3		.h	1 to 853	1 to 853	exact	RefSeq, AAA		853/853 (100 %)	0 diff (100 %id)
BM842627	lymph node, stomach	.h	1 to 581	1 to 580	exact			580/580 (100 %)	2 diff (99.7 %id)
BM761575	myeloma	.h	1 to 232	1 to 232				232/232 (100 %)	0 diff (100 %id)
BM849536	myeloma	.h	1 to 703	1 to 703	exact	tiling clone,		703/703 (100 %)	0 diff (100 %id)
BM785265	myeloma	.h	1 to 575	1 to 574	Q2A			574/574 (100 %)	1 diff (99.9 %id)
BM761836	lymph node, stomach	.h	2 to 208	1 to 205				205/205 (100 %)	3 diff (98.6 %id)
BM924222	pooled colon, kidney, stomach	.h	4 to 835	19 to 852	exact			834/881 (94 %)	14 diff (98.5 %id)
CD050944	embryonic trophoblasts, made from WA01 stemcells	.h	5 to 799	20 to 821	exact	AAA		802/862 (93 %)	17 diff (98.1 %id)
BM913383	amelanotic melanoma, cell line, skin	.h	5 to 800	15 to 821	exact			807/1067 (75 %)	34 diff (96.9 %id)
BM914702	amelanotic melanoma, cell line, skin	.h	5 to 594	1 to 592	exact			592/1281 (46 %)	18 diff (98.6 %id)
CN266378	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	7 to 737	1 to 733	exact			733/733 (100 %)	3 diff (99.6 %id)
BQ787789	insulinoma, Pancreas	.h	7 to 526	1 to 520	exact	fully sequenced,		520/520 (100 %)	5 diff (99.1 %id)
BQ961868	epithelioid carcinoma cell line, Pancreas	.h	7 to 835	1 to 843	A22P			843/940 (89 %)	28 diff (97.1 %id)
CR602072	neuroblastoma	.h	8 to 835	1 to 828	exact			828/828 (100 %)	0 diff (100 %id)
BM423459	amelanotic melanoma, cell line, skin	.h	11 to 830	1 to 832	exact	AAA		832/832 (100 %)	17 diff (98.0 %id)
BX416313	neuroblastoma	.h	12 to 835	6 to 828	C37F K85X Y86F C94F D95Y			823/829 (99 %)	20 diff (97.6 %id)
BM913540	amelanotic melanoma, cell line, skin	.h	13 to 828	1 to 814	exact	AAA		814/814 (100 %)	2 diff (99.8 %id)
BM821995	stomach	.h	13 to 221	1 to 208				208/208 (100 %)	1 diff (99.6 %id)
BG750759	eye, normal pigmented retinal epithelium	.h	14 to 671	1 to 660	K142T D143R			660/662 (99 %)	4 diff (99.4 %id)
BG830977	epithelioid carcinoma cell line, Pancreas	.h	14 to 798	1 to 781	P33R S35A E36S C37A A38L ...			781/810 (96 %)	11 diff (98.7 %id)
BM423353	amelanotic melanoma, cell line, skin	.h	14 to 828	1 to 815	exact	AAA		815/815 (100 %)	4 diff (99.6 %id)
CN266362	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	15 to 657	9 to 651	exact			643/651 (98 %)	11 diff (98.4 %id)
CN266425	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	15 to 636	1 to 625	exact			625/625 (100 %)	5 diff (99.2 %id)
BQ069097	brain, neuroblastoma, cell line	.h	15 to 828	36 to 849	exact			814/1045 (77 %)	8 diff (99.3 %id)
BM750349	stomach	.h	15 to 565	1 to 551	exact			551/551 (100 %)	0 diff (100 %id)
AA232437	brain, neuroepithelial cells	.h	16 to 358	1 to 341				341/341 (100 %)	9 diff (97.4 %id)
BM782080	myeloma	.h	16 to 520	1 to 505				505/505 (100 %)	2 diff (99.7 %id)
BM849847	myeloma	.h	16 to 520	1 to 505				505/505 (100 %)	0 diff (100 %id)
BM789630	stomach	.h	16 to 635	1 to 620	exact			620/620 (100 %)	0 diff (100 %id)
BM790596	stomach	.h	16 to 657	1 to 642	Q64H			642/642 (100 %)	1 diff (99.9 %id)
BM850479	stomach	.h	16 to 703	1 to 688	exact			688/692 (99 %)	4 diff (99.5 %id)
CN266483	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	17 to 718	1 to 702	exact			702/702 (100 %)	2 diff (99.8 %id)
BM781843	myeloma	.h	17 to 570	1 to 554	K101X			554/554 (100 %)	1 diff (99.9 %id)
BM785320	stomach	.h	17 to 597	1 to 581	exact			581/581 (100 %)	1 diff (99.9 %id)
BM790202	stomach	.h	17 to 635	1 to 621	K133X			621/621 (100 %)	3 diff (99.6 %id)
BM850649	stomach	.h	17 to 635	1 to 619	exact			619/619 (100 %)	1 diff (99.9 %id)
CD049399	embryonic stem cells, WA01, passage 38	.h	18 to 829	23 to 836	K23R K135*	tiling clone, AAA		814/836 (97 %)	11 diff (98.7 %id)
CN266452	embryonic stem cells, DMSO-treated H9 cellline	.h	19 to 704	1 to 686	exact			686/686 (100 %)	1 diff (99.9 %id)
BM760397	lymph node, stomach	.h	20 to 521	1 to 502				502/502 (100 %)	0 diff (100 %id)
CN266368	embryonic stem cells, DMSO-treated H9 cellline	.h	22 to 769	1 to 748	exact			748/748 (100 %)	5 diff (99.4 %id)
TI_149285949		.h	23 to 828	882 to 85	R4X F6S L7S L8S L9H ...	AAA		798/804 (99 %)	14 diff (98.3 %id)
BU783346	insulinoma, Pancreas	.h	25 to 520	1 to 496				496/496 (100 %)	4 diff (99.2 %id)
CN266399	embryonic stem cells, cell lines H1, H7, andH9	.h	28 to 658	13 to 644	S35E E36R C37V A38R E39*			632/644 (98 %)	7 diff (99.0 %id)
CN266460	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	28 to 566	1 to 539	exact			539/539 (100 %)	1 diff (99.9 %id)
BU184627	leiomyosarcoma, uterus	.h	28 to 783	35 to 804	exact			770/926 (83 %)	34 diff (96.4 %id)
BG830798	epithelioid carcinoma cell line, Pancreas	.h	29 to 713	1 to 684	exact			684/684 (100 %)	6 diff (99.2 %id)
BQ307873	breast	.h	30 to 292	37 to 299				263/299 (87 %)	19 diff (93.7 %id)
CN266343	embryonic stem cells, DMSO-treated H9 cellline	.h	30 to 747	1 to 719	exact			719/719 (100 %)	3 diff (99.6 %id)
CR614410	Neuroblastoma Cot 25-normalized	.h	30 to 835	1 to 806	exact			806/806 (100 %)	0 diff (100 %id)
AL528378	brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized	.h	30 to 835	1 to 804	C37F C45A T46P S48A S49A ...			804/805 (99 %)	11 diff (98.7 %id)
BI523831	pooled lung and spleen	.h	30 to 840	1 to 817	exact			817/884 (92 %)	14 diff (98.5 %id)
TI_44159426		.h	30 to 840	30 to 846	exact			817/913 (89 %)	20 diff (97.9 %id)
CN266408	embryonic stem cells, DMSO-treated H9 cellline	.h	31 to 590	1 to 560	exact			560/560 (100 %)	0 diff (100 %id)
CN266431	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	31 to 566	1 to 536	exact			536/536 (100 %)	4 diff (99.3 %id)
BQ932417	epidermoid carcinoma, cell line, lung	.h	32 to 802	1 to 791	C94G C126L T127H K129Q T130D ...			791/998 (79 %)	30 diff (97.0 %id)
BQ955533	epidermoid carcinoma, cell line, lung	.h	32 to 830	1 to 807	exact	AAA		807/807 (100 %)	13 diff (98.4 %id)
BQ307332	breast	.h	33 to 312	16 to 292				277/292 (94 %)	21 diff (92.9 %id)
CD389765	embryonic trophoblasts, made from WA01 stemcells	.h	36 to 835	24 to 825	G92V A93R C94V D95M G97A ...	AAA		802/901 (89 %)	16 diff (98.3 %id)
CD387595	embryonic trophoblasts, made from WA01 stemcells	.h	37 to 828	11 to 802	exact	AAA		792/802 (98 %)	8 diff (99.1 %id)
CN266361	embryonic stem cells, DMSO-treated H9 cellline	.h	37 to 779	1 to 743	exact			743/743 (100 %)	5 diff (99.4 %id)
CN266375	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	37 to 722	1 to 686	exact			686/686 (100 %)	2 diff (99.8 %id)
AA075883		.h	37 to 387	1 to 348		fully sequenced,		348/348 (100 %)	29 diff (91.7 %id)
AW163233	brain, frontal lobe	.h	37 to 431	1 to 396		fully sequenced,		396/396 (100 %)	1 diff (99.8 %id)
BU179690	ductal carcinoma, cell line, Pancreas	.h	39 to 831	1 to 796	exact	AAA		796/796 (100 %)	8 diff (99.0 %id)
CB109442	Liver	.h	41 to 287	1 to 247				247/247 (100 %)	4 diff (98.4 %id)
AU129491		.h	42 to 376	2 to 334		fully sequenced, capped		333/333 (100 %)	4 diff (98.8 %id)
CN266444	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	43 to 699	1 to 656	exact			656/656 (100 %)	5 diff (99.3 %id)
AU126631		.h	43 to 537	2 to 495	K137R K140X G141E K142R D143I	capped		494/495 (99 %)	9 diff (98.2 %id)
CN266367	embryonic stem cells, DMSO-treated H9 cellline	.h	44 to 667	9 to 632	exact			624/632 (98 %)	8 diff (98.8 %id)
CN266479	embryonic stem cells, DMSO-treated H9 cellline	.h	44 to 398	1 to 355				355/355 (100 %)	0 diff (100 %id)
BQ689983	ductal carcinoma, cell line, Pancreas	.h	44 to 828	1 to 785	exact	AAA		785/785 (100 %)	1 diff (99.9 %id)
BQ889499	ductal carcinoma, cell line, Pancreas	.h	44 to 835	1 to 800	exact			800/939 (85 %)	18 diff (98.1 %id)
CB120838	cervix, Uterine	.h	45 to 370	1 to 326				326/326 (100 %)	3 diff (99.1 %id)
CD050086	embryonic trophoblasts, made from WA01 stemcells	.h	45 to 835	26 to 819	exact	AAA		794/881 (90 %)	16 diff (98.2 %id)
CD176858	embryonic trophoblasts, made from WA01 stemcells	.h	45 to 831	19 to 805	exact	AAA		787/805 (97 %)	9 diff (98.9 %id)
CN266432	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	45 to 546	1 to 502	exact			502/502 (100 %)	5 diff (99.1 %id)
AL697846	human skeletal muscle	.h	45 to 830	1 to 793	F56L R57H	AAA		793/793 (100 %)	12 diff (98.5 %id)
BP249594	Kidney	.h	45 to 449	1 to 405				405/408 (99 %)	4 diff (99.1 %id)
BM773261	Ascites, stomach	.h	45 to 441	1 to 397				397/397 (100 %)	0 diff (100 %id)
BM782137	myeloma	.h	45 to 580	1 to 536	exact			536/536 (100 %)	0 diff (100 %id)
BP374141	umbilical cord	.h	45 to 625	1 to 581	exact			581/581 (100 %)	0 diff (100 %id)
CN266348	embryonic stem cells, cell lines H1, H7, andH9	.h	46 to 554	1 to 509	G5V			509/509 (100 %)	5 diff (99.1 %id)
CN266455	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	46 to 703	1 to 658	exact			658/658 (100 %)	1 diff (99.9 %id)
AL523055	brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized	.h	46 to 835	40 to 826	H3P K24X K50Q K78X K85X ...			787/827 (95 %)	20 diff (97.6 %id)
AU126400		.h	46 to 521	2 to 477		capped		476/486 (97 %)	11 diff (97.8 %id)
AU126743		.h	46 to 595	2 to 551	exact	capped		550/552 (99 %)	14 diff (97.5 %id)
AU126776		.h	46 to 585	2 to 548	G139R K140G G141R K142E D143R	capped		547/548 (99 %)	18 diff (96.8 %id)
AU129753		.h	46 to 833	2 to 797	exact	fully sequenced, capped		796/796 (100 %)	16 diff (98.0 %id)
BM789652	stomach	.h	46 to 704	1 to 659	exact			659/659 (100 %)	0 diff (100 %id)
BM791426	stomach	.h	46 to 587	1 to 542	exact			542/542 (100 %)	0 diff (100 %id)
BM850825	stomach	.h	46 to 282	1 to 237				237/240 (98 %)	1 diff (99.6 %id)
BM850609	stomach	.h	46 to 575	1 to 530	D83H K129N			530/530 (100 %)	4 diff (99.3 %id)
CN266384	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	47 to 658	1 to 612	exact			612/612 (100 %)	4 diff (99.4 %id)
CN266402	embryonic stem cells, DMSO-treated H9 cellline	.h	47 to 828	1 to 783	exact			783/784 (99 %)	5 diff (99.4 %id)
CN266403	embryonic stem cells, DMSO-treated H9 cellline	.h	47 to 379	1 to 333				333/333 (100 %)	3 diff (99.1 %id)
BF032696	adenocarcinoma, ovary	.h	47 to 826	1 to 769	A20D V21G A22R K23Q K25E ...			769/811 (94 %)	40 diff (95.1 %id)
BE908959	epithelioid carcinoma, Pancreas	.h	47 to 835	1 to 790	exact			790/828 (95 %)	33 diff (96.1 %id)
CB111177	Liver	.h	47 to 413	1 to 367				367/367 (100 %)	0 diff (100 %id)
CN266465	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	48 to 472	1 to 426				426/426 (100 %)	1 diff (99.8 %id)
BG683279	brain, neuroblastoma, cell line	.h	48 to 684	1 to 637	exact			637/639 (99 %)	2 diff (99.7 %id)
CN266427	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	49 to 672	1 to 624	exact			624/624 (100 %)	3 diff (99.6 %id)
CN266453	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	49 to 680	2 to 632	exact			631/632 (99 %)	5 diff (99.3 %id)
CN266469	embryonic stem cells, cell lines H1, H7, andH9	.h	49 to 413	12 to 376				365/376 (97 %)	6 diff (98.5 %id)
BF033796	adenocarcinoma, ovary	.h	50 to 825	1 to 772	K24I K25E D26R K27*	AAA		772/772 (100 %)	40 diff (94.9 %id)
BE908776	epithelioid carcinoma, Pancreas	.h	50 to 636	1 to 587	K30T K140N G141A K142Q			587/588 (99 %)	5 diff (99.2 %id)
CN266357	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	51 to 751	10 to 710	exact			701/710 (98 %)	7 diff (99.1 %id)
CN266416	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	52 to 691	1 to 640	exact			640/640 (100 %)	0 diff (100 %id)
BM730021	insulinoma, Pancreas	.h	52 to 414	8 to 370				363/370 (98 %)	9 diff (97.6 %id)
CN266347	embryonic stem cells, DMSO-treated H9 cellline	.h	53 to 416	1 to 364				364/364 (100 %)	0 diff (100 %id)
CN266382	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	53 to 694	1 to 642	exact			642/642 (100 %)	0 diff (100 %id)
CR624204	Neuroblastoma Cot 25-normalized	.h	53 to 835	1 to 783	exact			783/783 (100 %)	0 diff (100 %id)
AL523011	brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized	.h	53 to 774	726 to 1	L12P A13R L14P L15X A16G ...			726/726 (100 %)	28 diff (96.2 %id)
AL523012	brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized	.h	53 to 827	1 to 774	L17P D95E Y112N			774/774 (100 %)	10 diff (98.8 %id)
DN994951	brain, whole brain	.h	54 to 663	1 to 610	exact			610/610 (100 %)	4 diff (99.4 %id)
AU126752		.h	55 to 601	2 to 548	K140X	capped		547/547 (100 %)	8 diff (98.6 %id)
AA364687	pineal body	.h	56 to 355	1 to 300				300/301 (99 %)	3 diff (99.1 %id)
BC011704	Uterus, endometrium adenocarcinoma	.h	56 to 828	1 to 773	exact	available from MGC, AAA		773/773 (100 %)	0 diff (100 %id)
CN266374	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	56 to 827	1 to 771	exact			771/771 (100 %)	2 diff (99.8 %id)
CN266409	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	56 to 787	1 to 734	exact			734/734 (100 %)	3 diff (99.6 %id)
BG339806	leiomyosarcoma cell line, uterus	.h	56 to 685	1 to 630	C126X			630/957 (65 %)	4 diff (99.6 %id)
CN266364	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	57 to 692	1 to 636	exact			636/636 (100 %)	1 diff (99.9 %id)
CN266457	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	57 to 587	1 to 531	D26N			531/531 (100 %)	3 diff (99.5 %id)
CN266481	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.h	57 to 726	11 to 681	exact			671/681 (98 %)	8 diff (98.9 %id)
CA942334	Pancreas, Purified pancreatic islet	.h	59 to 528	1 to 470	exact	fully sequenced,		470/470 (100 %)	0 diff (100 %id)
BU557038	ovary, teratocarcinoma, cell line	.h	59 to 830	1 to 775	exact	AAA		775/775 (100 %)	5 diff (99.4 %id)
BE312284	brain, neuroblastoma	.h	61 to 758	1 to 708	K138T K140N D143G			708/775 (91 %)	28 diff (96.4 %id)
BF033808	adenocarcinoma, ovary	.h	62 to 821	1 to 765	L15S A16G L17A T18H S19L ...			729/766 (95 %)	47 diff (93.9 %id)
BE736100	adenocarcinoma, Pancreas	.h	63 to 751	1 to 678	C126L T127H K129Q T130R K131P ...	AAA		674/739 (91 %)	27 diff (96.4 %id)
BM830289	lymph node, stomach	.h	64 to 402	1 to 340				340/340 (100 %)	9 diff (97.4 %id)
CN266439	embryonic stem cells, DMSO-treated H9 cellline	.h	66 to 691	1 to 627	exact			627/627 (100 %)	5 diff (99.3 %id)
CN266448	embryonic stem cells, DMSO-treated H9 cellline	.h	67 to 739	1 to 674	exact			674/685 (98 %)	10 diff (98.6 %id)
X55110	brain	.h	67 to 853	1 to 786	exact	tiling clone, AAA		786/786 (100 %)	3 diff (99.7 %id)
CN266349	embryonic stem cells, DMSO-treated H9 cellline	.h	71 to 714	1 to 644	exact			644/644 (100 %)	0 diff (100 %id)
CN266410	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	71 to 711	9 to 653	exact			645/653 (98 %)	5 diff (99.3 %id)
CN266412	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	71 to 685	1 to 616	exact			616/616 (100 %)	4 diff (99.4 %id)
CN266470	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	71 to 258	10 to 197				188/197 (95 %)	6 diff (97.0 %id)
CN266480	embryonic stem cells, DMSO-treated H9 cellline	.h	71 to 406	1 to 336				336/336 (100 %)	0 diff (100 %id)
CN266417	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	72 to 572	1 to 502	S35Q E36R C37V A38R E39*			502/502 (100 %)	3 diff (99.5 %id)
CN266422	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	72 to 827	1 to 753	exact			753/753 (100 %)	5 diff (99.4 %id)
CD105980	brain, Pituitary	.h	72 to 835	1 to 764	exact			764/792 (96 %)	4 diff (99.5 %id)
BE294834	muscle, rhabdomyosarcoma	.h	74 to 595	1 to 523	R57L E58R T60H C61L G62R ...			523/523 (100 %)	1 diff (99.9 %id)
CN266415	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	75 to 322	1 to 248				248/248 (100 %)	0 diff (100 %id)
BP421157	small intestine	.h	75 to 585	1 to 511	exact		Submitted on the opposite strand	511/511 (100 %)	1 diff (99.9 %id)
BE379029	endometrium, adenocarcinoma cell line, uterus	.h	75 to 826	1 to 754	exact			754/754 (100 %)	15 diff (98.1 %id)
BF036785	adenocarcinoma, ovary	.h	75 to 737	1 to 664	C52A G53A V54W G55V F56S ...			664/666 (99 %)	12 diff (98.2 %id)
CN266383	embryonic stem cells, DMSO-treated H9 cellline	.h	77 to 415	1 to 339				339/339 (100 %)	0 diff (100 %id)
CN266350	embryonic stem cells, DMSO-treated H9 cellline	.h	78 to 825	1 to 750	exact			750/750 (100 %)	3 diff (99.6 %id)
CN266355	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	78 to 318	1 to 241				241/241 (100 %)	1 diff (99.6 %id)
CN266372	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	78 to 828	1 to 754	R69L	AAA		754/754 (100 %)	5 diff (99.4 %id)
CN266391	embryonic stem cells, DMSO-treated H9 cellline	.h	78 to 673	1 to 596	exact			596/596 (100 %)	1 diff (99.9 %id)
CN266413	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	78 to 395	1 to 318				318/318 (100 %)	1 diff (99.7 %id)
CN266426	embryonic stem cells, DMSO-treated H9 cellline	.h	78 to 787	1 to 709	exact			709/714 (99 %)	2 diff (99.8 %id)
CN266435	embryonic stem cells, DMSO-treated H9 cellline	.h	78 to 709	1 to 634	exact			634/634 (100 %)	7 diff (98.9 %id)
CN266441	embryonic stem cells, DMSO-treated H9 cellline	.h	78 to 603	1 to 526	exact			526/526 (100 %)	2 diff (99.7 %id)
CN266446	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	78 to 634	1 to 557	exact			557/557 (100 %)	0 diff (100 %id)
CN266458	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	78 to 500	1 to 423				423/423 (100 %)	0 diff (100 %id)
CN266467	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	78 to 683	1 to 606	exact			606/606 (100 %)	0 diff (100 %id)
CN266472	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	78 to 674	1 to 597	exact			597/597 (100 %)	0 diff (100 %id)
CN266484	embryonic stem cells, DMSO-treated H9 cellline	.h	78 to 554	1 to 477	exact			477/477 (100 %)	1 diff (99.8 %id)
CN266492	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	78 to 657	1 to 580	exact			580/580 (100 %)	1 diff (99.9 %id)
CN266370	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	81 to 631	1 to 551	exact			551/551 (100 %)	0 diff (100 %id)
BE315082	adenocarcinoma cell line, ovary	.h	81 to 715	1 to 636	K138N G139R K140E D143G			636/637 (99 %)	9 diff (98.6 %id)
BQ277681	ovary, teratocarcinoma, cell line	.h	81 to 828	1 to 748	exact	AAA		748/748 (100 %)	5 diff (99.4 %id)
CN266419	embryonic stem cells, DMSO-treated H9 cellline	.h	83 to 741	1 to 660	exact			660/660 (100 %)	2 diff (99.7 %id)
CN266366	embryonic stem cells, DMSO-treated H9 cellline	.h	86 to 742	1 to 658	exact			658/658 (100 %)	2 diff (99.7 %id)
CN266345	embryonic stem cells, DMSO-treated H9 cellline	.h	87 to 463	1 to 377				377/377 (100 %)	0 diff (100 %id)
CN266351	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	87 to 532	1 to 446	exact			446/446 (100 %)	0 diff (100 %id)
CN266373	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.h	87 to 773	1 to 688	exact			688/688 (100 %)	1 diff (99.9 %id)
AA069239	Pancreas	.h	88 to 272	1 to 190				190/190 (100 %)	11 diff (94.3 %id)
AU151595		.h	346 to 828	479 to 1		fully sequenced,		479/479 (100 %)	7 diff (98.6 %id)
AA071541		.h	373 to 828	460 to 1		fully sequenced,		460/460 (100 %)	6 diff (98.7 %id)
AW157228	brain, frontal lobe	.h	401 to 835	436 to 2		fully sequenced,		435/436 (99 %)	0 diff (100 %id)
BQ787607	insulinoma, Pancreas	.h	467 to 828	378 to 17		fully sequenced, AAA		362/362 (100 %)	0 diff (100 %id)
CA867040	Pancreas, Purified pancreatic islet	.h	467 to 827	361 to 1		fully sequenced,		361/361 (100 %)	0 diff (100 %id)
AA232438	brain, neuroepithelial cells	.h	496 to 695	203 to 1				203/233 (87 %)	14 diff (94.0 %id)
AA069147	Pancreas	.h	534 to 828	299 to 1				299/299 (100 %)	6 diff (98.0 %id)
AU151827		.h	571 to 828	258 to 1		fully sequenced,		258/258 (100 %)	1 diff (99.7 %id)
AK130889	umbilical cord	.i	1 to 959	1 to 959	exact	tiling clone, available from FLJ,		959/959 (100 %)	0 diff (100 %id)
NM_001012334.1		.i	1 to 984	1 to 984	exact	RefSeq, AAA		984/984 (100 %)	0 diff (100 %id)
BP271152	small intestine	.i	140 to 616	1 to 477				477/484 (98 %)	2 diff (99.6 %id)
CN266478	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	213 to 958	1 to 747	exact			747/747 (100 %)	6 diff (99.2 %id)
BE905304	epithelioid carcinoma, Pancreas	.i	217 to 926	1 to 711	exact			711/748 (95 %)	18 diff (97.6 %id)
BE907027	epithelioid carcinoma, Pancreas	.i	217 to 894	1 to 680	exact			680/680 (100 %)	16 diff (97.7 %id)
BG829436	epithelioid carcinoma cell line, Pancreas	.i	220 to 966	1 to 745	V72C C74A N75T W76G K77R ...			745/779 (95 %)	13 diff (98.4 %id)
BX353467	Neuroblastoma Cot 25-normalized	.i	221 to 966	1 to 746	exact			746/746 (100 %)	0 diff (100 %id)
CN266380	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	222 to 855	7 to 640	exact			634/640 (99 %)	0 diff (100 %id)
CN266390	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	222 to 791	7 to 576	exact			570/576 (98 %)	1 diff (99.9 %id)
CN266395	embryonic stem cells, DMSO-treated H9 cellline	.i	222 to 818	7 to 603	exact			597/603 (99 %)	0 diff (100 %id)
CN266418	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.i	222 to 814	1 to 595	L8R C94V D95*			595/595 (100 %)	3 diff (99.5 %id)
AI936124	normal prostate, Prostate	.i	222 to 961	743 to 4	R4E G5X L7S L8S L9S ...			740/760 (97 %)	15 diff (98.1 %id)
BE881260	large cell carcinoma, undifferentiated, lung	.i	222 to 952	1 to 728	F6V			728/730 (99 %)	17 diff (97.7 %id)
BU844935	ovary, teratocarcinoma, cell line	.i	222 to 982	2 to 762	exact	AAA		761/762 (99 %)	0 diff (100 %id)
BU554130	ovary, teratocarcinoma, cell line	.i	222 to 959	57 to 795	R4*	AAA		739/795 (92 %)	10 diff (98.8 %id)
CV028369	mixed	.i	223 to 653	1 to 431				431/601 (71 %)	7 diff (98.9 %id)
M69148	Kidney	.i	223 to 783	1 to 561	exact			561/562 (99 %)	1 diff (99.9 %id)
CN266398	embryonic stem cells, DMSO-treated H9 cellline	.i	224 to 909	1 to 687				687/687 (100 %)	2 diff (99.8 %id)
BE048096	brain, tumor, 5 pooled (see description)	.i	226 to 704	1 to 479				479/479 (100 %)	0 diff (100 %id)
CN266430	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	227 to 727	1 to 501				501/503 (99 %)	3 diff (99.5 %id)
BF035189	adenocarcinoma, ovary	.i	227 to 797	1 to 585				585/1077 (54 %)	25 diff (97.7 %id)
CN266449	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	228 to 835	1 to 608				608/615 (98 %)	1 diff (99.9 %id)
AA126127		.i	228 to 658	1 to 432		fully sequenced,		432/432 (100 %)	9 diff (98.0 %id)
BG753264	eye, normal pigmented retinal epithelium	.i	230 to 883	1 to 654				654/655 (99 %)	2 diff (99.7 %id)
CN266360	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	232 to 960	1 to 730				730/730 (100 %)	2 diff (99.8 %id)
CN266440	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	234 to 640	1 to 407				407/407 (100 %)	2 diff (99.6 %id)
CN266442	embryonic stem cells, cell lines H1, H7, andH9	.i	234 to 817	1 to 584				584/587 (99 %)	4 diff (99.4 %id)
CN266358	embryonic stem cells, DMSO-treated H9 cellline	.i	235 to 705	1 to 470				470/470 (100 %)	3 diff (99.4 %id)
CN266393	embryonic stem cells, DMSO-treated H9 cellline	.i	235 to 648	1 to 414				414/414 (100 %)	1 diff (99.8 %id)
CN266420	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	235 to 709	1 to 475				475/475 (100 %)	0 diff (100 %id)
CN266482	embryonic stem cells, DMSO-treated H9 cellline	.i	235 to 654	25 to 444				420/444 (94 %)	6 diff (98.7 %id)
CN266485	embryonic stem cells, DMSO-treated H9 cellline	.i	235 to 699	1 to 466				466/466 (100 %)	1 diff (99.8 %id)
CN266401	embryonic stem cells, DMSO-treated H9 cellline	.i	236 to 809	1 to 574				574/574 (100 %)	1 diff (99.9 %id)
CN266450	embryonic stem cells, DMSO-treated H9 cellline	.i	237 to 697	1 to 461				461/465 (99 %)	2 diff (99.6 %id)
CN266387	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	238 to 650	1 to 413				413/413 (100 %)	0 diff (100 %id)
BQ268091	insulinoma, Pancreas	.i	240 to 659	1 to 420		fully sequenced,		420/420 (100 %)	5 diff (98.9 %id)
TI_149286042		.i	241 to 959	811 to 95		AAA		717/791 (90 %)	19 diff (97.6 %id)
BI524069	pooled lung and spleen	.i	242 to 910	90 to 762				673/762 (88 %)	11 diff (98.6 %id)
TI_44159952		.i	242 to 910	123 to 795				673/795 (84 %)	11 diff (98.7 %id)
CN266392	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	256 to 958	1 to 704				704/704 (100 %)	2 diff (99.8 %id)
BF684205	leiomyosarcoma cell line, uterus	.i	256 to 988	1 to 730				730/855 (85 %)	14 diff (98.4 %id)
CN266397	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	258 to 886	1 to 629				629/629 (100 %)	3 diff (99.6 %id)
CN266423	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	265 to 945	1 to 681				681/681 (100 %)	0 diff (100 %id)
CN266468	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	267 to 957	1 to 691				691/691 (100 %)	2 diff (99.8 %id)
BM711194	eye, fetal eyes	.i	267 to 497	9 to 239		fully sequenced,		231/239 (96 %)	7 diff (97.1 %id)
BU626178	cell lines, Enchondroma	.i	272 to 959	705 to 19		AAA		687/687 (100 %)	1 diff (99.9 %id)
CN266437	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	288 to 720	4 to 436				433/436 (99 %)	0 diff (100 %id)
AL536136	brain, fetal brain	.i	296 to 966	1 to 670				670/671 (99 %)	5 diff (99.3 %id)
BX395389	Neuroblastoma Cot 50-normalized	.i	297 to 966	1 to 668				668/669 (99 %)	29 diff (95.7 %id)
CD673196	eye, Iris	.i	297 to 655	105 to 463				359/463 (77 %)	9 diff (98.1 %id)
AA846556	parathyroid gland, parathyroid tumor	.i	297 to 959	676 to 12		AAA		665/684 (97 %)	25 diff (96.4 %id)
AI246564	pharynx, squamous cell carcinoma	.i	297 to 961	663 to 1				663/707 (93 %)	10 diff (98.6 %id)
TI_149285220		.i	297 to 959	753 to 91		AAA		663/1105 (60 %)	17 diff (98.5 %id)
TI_149288519		.i	297 to 960	712 to 50		AAA		663/687 (96 %)	15 diff (97.9 %id)
TI_149291693		.i	297 to 959	738 to 83		AAA		656/694 (94 %)	8 diff (98.9 %id)
AW167783	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.i	299 to 959	659 to 1				659/659 (100 %)	20 diff (97.0 %id)
BM760043	lymph node, stomach	.i	299 to 805	1 to 509				509/509 (100 %)	5 diff (99.1 %id)
BM760288	lymph node, stomach	.i	299 to 887	1 to 589				589/589 (100 %)	0 diff (100 %id)
BM841344	lymph node, stomach	.i	299 to 805	1 to 507				507/507 (100 %)	2 diff (99.7 %id)
BM838414	lymph node, stomach	.i	299 to 825	1 to 527				527/527 (100 %)	0 diff (100 %id)
BF115257	fibrotheoma, ovary	.i	300 to 961	663 to 1				663/679 (97 %)	20 diff (97.1 %id)
CN266488	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	303 to 870	1 to 568				568/568 (100 %)	0 diff (100 %id)
CN266473	embryonic stem cells, DMSO-treated H9 cellline	.i	306 to 953	1 to 648				648/654 (99 %)	1 diff (99.9 %id)
CN266353	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.i	310 to 820	1 to 510				510/510 (100 %)	2 diff (99.7 %id)
CN266359	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.i	312 to 984	1 to 672		AAA		672/672 (100 %)	1 diff (99.9 %id)
CN266407	embryonic stem cells, DMSO-treated H9 cellline	.i	312 to 822	9 to 519				511/519 (98 %)	7 diff (98.7 %id)
BM796911	Ascites, stomach	.i	313 to 736	1 to 424				424/424 (100 %)	1 diff (99.8 %id)
BU682125	lung	.i	313 to 959	660 to 19		AAA		642/645 (99 %)	6 diff (99.1 %id)
CN266394	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	321 to 959	1 to 639				639/639 (100 %)	0 diff (100 %id)
AW170322	cervix, tumor	.i	322 to 958	636 to 1				636/647 (98 %)	44 diff (93.2 %id)
AA873153	2 pooled tumors (clear cell type), Kidney	.i	324 to 961	633 to 2				632/633 (99 %)	15 diff (97.7 %id)
BQ361351	ovary	.i	326 to 817	493 to 2				492/495 (99 %)	23 diff (95.4 %id)
AA340693	Kidney	.i	327 to 669	1 to 343				343/343 (100 %)	0 diff (100 %id)
AW167930	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.i	329 to 959	629 to 1				629/629 (100 %)	14 diff (97.8 %id)
CN266388	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	331 to 721	1 to 391				391/391 (100 %)	1 diff (99.8 %id)
BI524893	pooled lung and spleen	.i	331 to 896	590 to 13				578/809 (71 %)	25 diff (97.0 %id)
TI_44159954		.i	331 to 896	590 to 13				578/809 (71 %)	25 diff (97.0 %id)
CN266377	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	333 to 872	1 to 540				540/540 (100 %)	1 diff (99.9 %id)
AI814898	adenocarcinoma, Pancreas	.i	336 to 961	624 to 1				624/624 (100 %)	9 diff (98.6 %id)
TI_154034498		.i	342 to 948	712 to 111		AAA		602/751 (80 %)	6 diff (99.3 %id)
BM009733	amelanotic melanoma, cell line, skin	.i	346 to 959	1 to 615		AAA		615/615 (100 %)	3 diff (99.6 %id)
BM010630	amelanotic melanoma, cell line, skin	.i	346 to 961	1 to 616				616/634 (97 %)	4 diff (99.4 %id)
AW966037		.i	347 to 959	613 to 1			Submitted on the opposite strand	613/613 (100 %)	4 diff (99.4 %id)
BM553786	amelanotic melanoma, cell line, skin	.i	347 to 922	28 to 607				580/1177 (49 %)	25 diff (97.9 %id)
TI_59384503		.i	347 to 959	63 to 676		AAA		614/614 (100 %)	2 diff (99.7 %id)
TI_59385467		.i	347 to 961	59 to 673				615/772 (79 %)	3 diff (99.7 %id)
CN266443	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	348 to 958	1 to 611				611/611 (100 %)	1 diff (99.9 %id)
BM971789	lung	.i	349 to 959	627 to 19		AAA		609/609 (100 %)	2 diff (99.7 %id)
BU185981	epidermoid carcinoma, cell line, salivary gland	.i	350 to 982	674 to 35		AAA	Submitted on the opposite strand	640/955 (67 %)	16 diff (98.4 %id)
AI672867	colon, colonic mucosa from 3 patients with Crohn'sdisease	.i	357 to 961	608 to 2				607/608 (99 %)	26 diff (95.8 %id)
BF058749	fibrotheoma, ovary	.i	358 to 959	602 to 1				602/602 (100 %)	2 diff (99.7 %id)
BU680894	lung	.i	358 to 959	619 to 19		AAA		601/601 (100 %)	2 diff (99.7 %id)
AA905511	pooled	.i	359 to 961	602 to 3				600/602 (99 %)	23 diff (96.2 %id)
BM984753	lung	.i	359 to 959	620 to 19		AAA		602/602 (100 %)	8 diff (98.7 %id)
BM998538	lung, Metastatic Chondrosarcoma	.i	360 to 959	617 to 19		AAA		599/599 (100 %)	2 diff (99.7 %id)
BF799608	colon_ins	.i	364 to 706	345 to 1			Submitted on the opposite strand	345/345 (100 %)	9 diff (97.4 %id)
BQ021188	lung, Metastatic Chondrosarcoma	.i	365 to 959	613 to 19		AAA		595/595 (100 %)	0 diff (100 %id)
AI653634	moderately-differentiated endometrialadenocarcinoma, 3 pooled tumors, uterus	.i	366 to 959	604 to 14		AAA		591/591 (100 %)	7 diff (98.9 %id)
CN266491	embryonic stem cells, DMSO-treated H9 cellline	.i	368 to 805	1 to 438				438/438 (100 %)	2 diff (99.6 %id)
AA837515	epithelium (cell line), Prostate	.i	369 to 959	617 to 33		AAA		585/585 (100 %)	43 diff (92.7 %id)
BI711129	insulinoma, Pancreas	.i	370 to 959	605 to 16		AAA		590/590 (100 %)	2 diff (99.7 %id)
AA670096	mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus	.i	377 to 911	1 to 532				532/532 (100 %)	9 diff (98.4 %id)
AA773276	mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus	.i	377 to 946	1 to 562				562/569 (98 %)	63 diff (89.0 %id)
BQ706596	Spleen	.i	384 to 959	1 to 576		AAA		576/576 (100 %)	0 diff (100 %id)
AW073723	2 pooled high-grade transitional celltumors, genitourinary tract	.i	385 to 966	583 to 4				580/583 (99 %)	13 diff (97.8 %id)
CN266476	embryonic stem cells, cell lines H1, H7, andH9	.i	392 to 956	565 to 1			Submitted on the opposite strand	565/565 (100 %)	0 diff (100 %id)
BQ361199	ovary	.i	405 to 811	1 to 405				405/405 (100 %)	7 diff (98.3 %id)
AA565888	colon, tumor	.i	407 to 959	545 to 1				545/545 (100 %)	11 diff (98.0 %id)
AA581813	germ cell tumor	.i	407 to 961	553 to 1				553/556 (99 %)	6 diff (99.0 %id)
AA622740	breast	.i	407 to 941	530 to 1				530/530 (100 %)	32 diff (94.0 %id)
AA657525		.i	412 to 959	556 to 12		AAA		545/545 (100 %)	14 diff (97.5 %id)
BE271931	adenocarcinoma cell line, ovary	.i	418 to 964	1 to 553				553/775 (71 %)	15 diff (98.1 %id)
AI675942	Prostate	.i	419 to 961	544 to 2				543/544 (99 %)	1 diff (99.9 %id)
AA947686	carcinoid, lung	.i	424 to 961	539 to 1				539/539 (100 %)	20 diff (96.3 %id)
AW439343	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.i	434 to 959	538 to 12		AAA		527/527 (100 %)	4 diff (99.3 %id)
AA677118	liver and spleen	.i	436 to 959	518 to 2				517/518 (99 %)	10 diff (98.1 %id)
BU737371	eye, fetal eyes	.i	436 to 959	541 to 18		fully sequenced, AAA		524/524 (100 %)	0 diff (100 %id)
BE765150	nervous_tumor	.i	438 to 721	284 to 1				284/287 (98 %)	3 diff (99.0 %id)
AA095763		.i	459 to 715	1 to 255				255/266 (95 %)	8 diff (97.0 %id)
AA834416	adenocarcinoma, colon	.i	464 to 784	321 to 1				321/334 (96 %)	14 diff (95.9 %id)
AA244008		.i	465 to 910	13 to 449				437/449 (97 %)	17 diff (96.3 %id)
AA856700	pharynx, squamous cell carcinoma	.i	465 to 961	486 to 1				486/487 (99 %)	17 diff (96.6 %id)
AI349513	lung	.i	465 to 961	505 to 3				503/527 (95 %)	12 diff (97.8 %id)
AW243736	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.i	465 to 961	495 to 1				495/499 (99 %)	15 diff (97.0 %id)
AA857612	epithelium (cell line), Prostate	.i	467 to 957	487 to 1				487/487 (100 %)	11 diff (97.8 %id)
AI288014	Kidney, renal cell tumor	.i	467 to 959	518 to 31		AAA		488/489 (99 %)	14 diff (97.2 %id)
CA443585	lung, Metastatic Chondrosarcoma	.i	467 to 959	509 to 19		AAA		491/491 (100 %)	4 diff (99.2 %id)
AA092202		.i	473 to 663	1 to 190				190/190 (100 %)	4 diff (97.9 %id)
W25583	lung	.i	473 to 681	1 to 213		fully sequenced,		213/213 (100 %)	0 diff (100 %id)
BM708882	eye, RPE and Choroid	.i	473 to 966	1 to 493				493/494 (99 %)	3 diff (99.4 %id)
AI564903	anaplastic oligodendroglioma, brain	.i	475 to 870	402 to 1				402/453 (88 %)	20 diff (95.6 %id)
BF036720	adenocarcinoma, ovary	.i	475 to 959	1 to 487		AAA		487/487 (100 %)	2 diff (99.6 %id)
BM697652	eye, fetal eyes	.i	480 to 959	1 to 480		AAA		480/480 (100 %)	0 diff (100 %id)
AA605069	adrenal adenoma, adrenal gland	.i	482 to 959	477 to 1				477/477 (100 %)	4 diff (99.2 %id)
W76149	heart	.i	487 to 946	1 to 463				463/463 (100 %)	8 diff (98.3 %id)
BF155224	breast	.i	494 to 816	357 to 30				328/366 (89 %)	4 diff (99.0 %id)
BF155259	breast	.i	494 to 816	18 to 338				321/349 (91 %)	7 diff (98.0 %id)
BF743525	breast	.i	494 to 816	18 to 348				331/357 (92 %)	8 diff (97.8 %id)
BF743584	breast	.i	494 to 816	12 to 335				324/360 (90 %)	8 diff (97.8 %id)
BF743597	breast	.i	494 to 815	335 to 13			Submitted on the opposite strand	323/346 (93 %)	0 diff (100 %id)
CN266363	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.i	495 to 959	20 to 484		AAA		465/484 (96 %)	8 diff (98.4 %id)
BF761628	colon_est	.i	497 to 816	1 to 321				321/327 (98 %)	3 diff (99.1 %id)
AI350498	pooled germ cell tumors	.i	497 to 961	465 to 1				465/465 (100 %)	5 diff (99.0 %id)
AW473570	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.i	497 to 966	476 to 6				471/476 (98 %)	9 diff (98.2 %id)
AI354687	lung	.i	498 to 960	463 to 1				463/463 (100 %)	1 diff (99.8 %id)
DB567247	hypothalamus	.i	502 to 959	1 to 458			Submitted on the opposite strand	458/458 (100 %)	0 diff (100 %id)
BF743523	breast	.i	503 to 822	44 to 366				323/370 (87 %)	19 diff (94.9 %id)
BE350678	2 pooled Wilms' tumors, one primary and onemetastatic to brain, Kidney	.i	505 to 959	466 to 12		AAA		455/559 (81 %)	25 diff (95.6 %id)
CN266414	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	506 to 959	1 to 454		AAA		454/454 (100 %)	3 diff (99.4 %id)
AI344761	2 pooled tumors (clear cell type), Kidney	.i	506 to 961	458 to 3				456/458 (99 %)	0 diff (100 %id)
AI351481		.i	506 to 915	413 to 1				413/417 (99 %)	16 diff (96.2 %id)
AI546836	Prostate	.i	507 to 966	1 to 463				463/475 (97 %)	12 diff (97.5 %id)
AI546843	Prostate	.i	507 to 966	1 to 464				464/714 (64 %)	7 diff (99.1 %id)
CN266405	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	507 to 966	1 to 460				460/463 (99 %)	16 diff (96.6 %id)
CN266381	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	510 to 959	8 to 457		AAA		450/457 (98 %)	6 diff (98.7 %id)
AV699411	hepatocellular carcinoma	.i	510 to 953	444 to 1				444/651 (68 %)	6 diff (99.1 %id)
AV700357. matches multiple genes	hepatocellular carcinoma	.i	510 to 938	429 to 1			also hits gene DOM3Z	429/643 (66 %)	1 diff (99.9 %id)
AV698390	hepatocellular carcinoma	.i	511 to 900	1 to 384				384/384 (100 %)	5 diff (98.7 %id)
AI363381	brain, glioblastoma (pooled)	.i	515 to 961	449 to 3				447/449 (99 %)	2 diff (99.6 %id)
AW182617	cervix, tumor	.i	516 to 958	443 to 1				443/443 (100 %)	2 diff (99.6 %id)
BM688870	eye, eye anterior segment	.i	516 to 960	9 to 453				445/453 (98 %)	6 diff (98.7 %id)
AA063086	pineal gland	.i	521 to 960	447 to 1				447/447 (100 %)	13 diff (97.1 %id)
AA330721	embryo	.i	522 to 700	1 to 179				179/179 (100 %)	0 diff (100 %id)
BE694608	breast	.i	527 to 797	275 to 7				269/275 (97 %)	1 diff (99.7 %id)
AI283102	placenta	.i	527 to 961	436 to 2				435/436 (99 %)	0 diff (100 %id)
CN266463	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	529 to 959	3 to 433		AAA		431/433 (99 %)	6 diff (98.7 %id)
AI560969	anaplastic oligodendroglioma, brain	.i	533 to 966	436 to 3				434/436 (99 %)	0 diff (100 %id)
BG110190	Bone, osteosarcoma, cell line	.i	535 to 959	1 to 425		AAA		425/425 (100 %)	0 diff (100 %id)
AI904529	breast	.i	539 to 866	330 to 3				328/332 (98 %)	1 diff (99.7 %id)
AI243590	pooled	.i	542 to 958	416 to 1				416/422 (98 %)	7 diff (98.4 %id)
BQ029211	lung, Metastatic Chondrosarcoma	.i	543 to 959	435 to 19		AAA		417/417 (100 %)	0 diff (100 %id)
AA092613		.i	545 to 868	1 to 316				316/319 (99 %)	10 diff (96.9 %id)
AA554302	colon	.i	547 to 959	413 to 1				413/413 (100 %)	1 diff (99.8 %id)
AI653485	ovary, tumor, 5 pooled (see description)	.i	549 to 959	411 to 1				411/415 (99 %)	0 diff (100 %id)
CN266371	embryonic stem cells, DMSO-treated H9 cellline	.i	550 to 858	1 to 309				309/309 (100 %)	4 diff (98.8 %id)
AA968896	Kidney, kidney tumor	.i	550 to 959	445 to 36		AAA		410/410 (100 %)	1 diff (99.8 %id)
AA160689	Pancreas	.i	556 to 989	432 to 1				432/432 (100 %)	5 diff (98.9 %id)
AI354641	poorly differentiated adenocarcinoma withsignet ring cell features, stomach	.i	558 to 959	403 to 1				403/403 (100 %)	3 diff (99.3 %id)
AI358308	moderately-differentiated endometrialadenocarcinoma, 3 pooled tumors, uterus	.i	562 to 961	399 to 2				398/399 (99 %)	6 diff (98.5 %id)
AA569487		.i	567 to 959	408 to 16		AAA		393/393 (100 %)	5 diff (98.8 %id)
AA775927		.i	570 to 959	391 to 1				391/391 (100 %)	9 diff (97.7 %id)
CN266344	embryonic stem cells, DMSO-treated H9 cellline	.i	573 to 960	1 to 388		AAA		388/388 (100 %)	2 diff (99.5 %id)
AA090244		.i	575 to 961	1 to 373				373/374 (99 %)	19 diff (95.0 %id)
AI302461	2 pooled tumors (clear cell type), Kidney	.i	576 to 959	382 to 1				382/382 (100 %)	3 diff (99.3 %id)
W19684	parathyroid gland, parathyroid tumor	.i	578 to 829	1 to 252		fully sequenced,		252/252 (100 %)	4 diff (98.5 %id)
BP242527	Liver	.i	579 to 960	1 to 382				382/386 (98 %)	4 diff (99.0 %id)
BG960321	colon	.i	581 to 713	1 to 134				134/134 (100 %)	9 diff (93.3 %id)
BF330544	breast_normal	.i	585 to 795	30 to 240				211/240 (87 %)	7 diff (97.1 %id)
AA650016	normal prostate, Prostate	.i	589 to 959	370 to 1				370/370 (100 %)	4 diff (99.0 %id)
CN266445	embryonic stem cells, DMSO-treated H9 cellline	.i	590 to 956	133 to 499				367/499 (73 %)	6 diff (98.8 %id)
N88126		.i	590 to 874	1 to 280				280/282 (99 %)	14 diff (95.1 %id)
BQ267839	insulinoma, Pancreas	.i	598 to 959	379 to 18		fully sequenced, AAA		362/362 (100 %)	0 diff (100 %id)
BQ267523	insulinoma, Pancreas	.i	610 to 959	1 to 350		AAA		350/350 (100 %)	4 diff (98.9 %id)
BQ272218	insulinoma, Pancreas	.i	615 to 959	362 to 18		AAA		345/349 (98 %)	0 diff (100 %id)
CK905930	insulinoma, Pancreas	.i	615 to 959	361 to 17		AAA		345/349 (98 %)	1 diff (99.8 %id)
AA550916	normal prostatic epithelial cells, Prostate	.i	616 to 959	365 to 22		AAA		344/344 (100 %)	13 diff (96.3 %id)
AI972309	Prostate	.i	617 to 913	297 to 1				297/297 (100 %)	3 diff (99.0 %id)
BI497291	cochlea, ear	.i	623 to 962	1 to 340		AAA		340/340 (100 %)	5 diff (98.6 %id)
AI869410	uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors	.i	624 to 960	336 to 1				336/380 (88 %)	12 diff (96.9 %id)
AA126065		.i	626 to 991	368 to 1		fully sequenced,		368/368 (100 %)	7 diff (98.1 %id)
AL520795	brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized	.i	627 to 990	1 to 363				363/364 (99 %)	2 diff (99.5 %id)
H99387	melanocyte	.i	627 to 959	337 to 1				337/460 (73 %)	10 diff (97.9 %id)
AA885582	carcinoid, lung	.i	627 to 961	335 to 2				334/339 (98 %)	0 diff (100 %id)
AI051519		.i	627 to 961	336 to 3				334/336 (99 %)	0 diff (100 %id)
AI363998	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.i	627 to 959	356 to 25		AAA		332/443 (74 %)	8 diff (98.2 %id)
AI689031	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.i	627 to 959	376 to 47		AAA		330/367 (89 %)	28 diff (92.4 %id)
BE866790	adenocarcinoma, colon	.i	627 to 954	1 to 328				328/328 (100 %)	0 diff (100 %id)
AA155767	Pancreas	.i	629 to 966	341 to 2				340/373 (91 %)	0 diff (100 %id)
BQ304538	breast	.i	630 to 816	24 to 219				196/228 (85 %)	10 diff (95.7 %id)
AA065174		.i	644 to 953	1 to 311				311/311 (100 %)	3 diff (99.1 %id)
AA659174		.i	644 to 984	8 to 347		AAA		340/347 (97 %)	6 diff (98.3 %id)
AA687198		.i	644 to 984	8 to 347		AAA		340/347 (97 %)	6 diff (98.3 %id)
T28360	colon, epididymis	.i	646 to 894	1 to 249				249/249 (100 %)	1 diff (99.6 %id)
AA921901	pooled	.i	648 to 961	314 to 1				314/314 (100 %)	3 diff (99.1 %id)
AA635808	normal prostate, Prostate	.i	650 to 959	309 to 1				309/309 (100 %)	5 diff (98.4 %id)
N92857	lung	.i	651 to 959	308 to 1		fully sequenced,		308/308 (100 %)	3 diff (99.1 %id)
AI970995	Prostate	.i	654 to 961	308 to 1				308/308 (100 %)	1 diff (99.7 %id)
AI494596	anaplastic oligodendroglioma, brain	.i	656 to 997	360 to 19		tiling clone, AAA		342/342 (100 %)	0 diff (100 %id)
AI784469	anaplastic oligodendroglioma, brain	.i	658 to 966	310 to 2				309/310 (99 %)	0 diff (100 %id)
AI566999	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.i	658 to 960	310 to 1				310/310 (100 %)	7 diff (97.8 %id)
AW170212	cervix	.i	658 to 959	313 to 12		AAA		302/302 (100 %)	18 diff (94.1 %id)
AA928381	pooled germ cell tumors	.i	664 to 958	300 to 6				295/300 (98 %)	0 diff (100 %id)
AI868371	pooled	.i	667 to 959	320 to 31		AAA		290/290 (100 %)	20 diff (93.2 %id)
CB854816	lung	.i	671 to 896	226 to 1				226/226 (100 %)	4 diff (98.3 %id)
CD251371	brain, Pituitary	.i	673 to 959	1 to 287		AAA		287/287 (100 %)	0 diff (100 %id)
CN266434	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	678 to 960	1 to 283		AAA		283/283 (100 %)	1 diff (99.7 %id)
AW150636	serous papillary carcinoma, high grade, 2pooled tumors, uterus	.i	684 to 961	283 to 5				279/283 (98 %)	0 diff (100 %id)
AV702749	adrenal gland	.i	687 to 959	1 to 272		AAA		272/272 (100 %)	3 diff (98.9 %id)
AW366864	head_neck	.i	698 to 858	164 to 4				161/165 (97 %)	0 diff (100 %id)
T54666	fetal spleen, Spleen	.i	704 to 961	261 to 4				258/261 (98 %)	0 diff (100 %id)
AI924384	lung, squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic)	.i	704 to 965	262 to 1				262/262 (100 %)	6 diff (97.8 %id)
C18016	placenta	.i	706 to 959	1 to 254				254/254 (100 %)	0 diff (100 %id)
BF114899	fibrotheoma, ovary	.i	707 to 959	270 to 18		AAA		253/253 (100 %)	2 diff (99.3 %id)
AA525365	prostate metastasis, liver	.i	709 to 959	1 to 251		AAA		251/251 (100 %)	5 diff (98.1 %id)
AI784640	uterus	.i	709 to 960	253 to 1				253/253 (100 %)	1 diff (99.7 %id)
AI758612	poorly-differentiated endometrialadenocarcinoma, 2 pooled tumors, uterus	.i	709 to 959	270 to 19		AAA		252/253 (99 %)	2 diff (99.3 %id)
AA528748	Kidney	.i	732 to 959	7 to 234		AAA		228/234 (97 %)	6 diff (97.5 %id)
CN266386	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	734 to 959	1 to 226		AAA		226/226 (100 %)	0 diff (100 %id)
BF063999	colon, colon tumor, RER+	.i	737 to 952	224 to 7				218/224 (97 %)	0 diff (100 %id)
BE832973	ovary	.i	761 to 891	134 to 5				130/134 (97 %)	0 diff (100 %id)
AA612817	colon, colon tumor RER+	.i	777 to 961	187 to 2				186/187 (99 %)	0 diff (100 %id)
BG153008	head/neck, nasopharyngeal carcinoma	.i	777 to 961	56 to 240				185/244 (75 %)	2 diff (99.2 %id)
BG055557	normal head/neck tissue	.i	777 to 961	56 to 240				185/244 (75 %)	1 diff (99.6 %id)
BG222691	head/neck, nasopharyngeal carcinoma	.i	789 to 961	179 to 5				175/179 (97 %)	0 diff (100 %id)
AW496797		.i	792 to 888	97 to 1				97/98 (98 %)	1 diff (99.0 %id)
AA292397	ovarian tumor, ovary	.i	792 to 941	1 to 150		fully sequenced,		150/150 (100 %)	0 diff (100 %id)
AA402706. matches multiple genes	ovarian tumor, ovary	.i	792 to 941	1 to 150			also hits gene WDR13	150/150 (100 %)	0 diff (100 %id)
BF434087	fibrotheoma, ovary	.i	794 to 966	173 to 2				172/173 (99 %)	0 diff (100 %id)
N90030	parathyroid gland, parathyroid tumor	.i	799 to 959	173 to 13		fully sequenced, AAA		161/161 (100 %)	0 diff (100 %id)
AI699968	pooled germ cell tumors	.i	813 to 959	161 to 15		AAA		147/147 (100 %)	0 diff (100 %id)
AA402271. matches multiple genes	ovarian tumor, ovary	.i	826 to 959	134 to 1			also hits gene CSNK1E	134/134 (100 %)	0 diff (100 %id)
AA720944	synovial sarcoma	.i	830 to 959	130 to 1				130/130 (100 %)	0 diff (100 %id)
CB410405	maxilla, pooled	.i	831 to 959	1 to 129		AAA		129/129 (100 %)	0 diff (100 %id)
CB409504	maxilla, pooled	.i	831 to 959	1 to 129		AAA		129/129 (100 %)	0 diff (100 %id)
CD523192	pooled	.i	832 to 963	1 to 132		AAA		132/132 (100 %)	1 diff (99.3 %id)
AI633889	pooled germ cell tumors	.i	865 to 959	116 to 22		AAA		95/95 (100 %)	0 diff (100 %id)
AI989937	pooled germ cell tumors	.i	865 to 959	114 to 20		AAA		95/95 (100 %)	2 diff (97.9 %id)
AA236707	ovarian tumor, ovary	.i	866 to 959	94 to 1		fully sequenced,		94/94 (100 %)	0 diff (100 %id)
CN266428	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.i	868 to 959	1 to 92		AAA		92/92 (100 %)	4 diff (95.7 %id)
CD520380	pooled	.i	868 to 991	1 to 124		AAA		124/124 (100 %)	7 diff (94.4 %id)
TI_57244537		.j	1 to 776	35 to 809	N113K A114C Q115S C116V Q117P ...			782/809 (96 %)	7 diff (99.2 %id)
BI915189	brain	.j	2 to 776	1 to 775	N113K A114C Q115S C116V Q117P ...	tiling clone,		775/775 (100 %)	2 diff (99.8 %id)
CN266352	embryonic stem cells, cell lines H1, H7, andH9	.j	14 to 483	9 to 481				473/481 (98 %)	7 diff (98.6 %id)
BQ921047	epidermoid carcinoma, cell line, lung	.j	18 to 680	1 to 668				668/980 (68 %)	18 diff (98.2 %id)
BP870930	embryonal kidney	.j	26 to 359	1 to 334				334/334 (100 %)	1 diff (99.8 %id)
BQ426079	leiomyosarcoma, uterus	.j	27 to 754	1 to 729				729/876 (83 %)	8 diff (99.1 %id)
DR763258	embryonic stem	.j	27 to 126	1 to 100				100/100 (100 %)	2 diff (98.0 %id)
CX870295	embryonic stem	.j	40 to 599	1 to 560				560/560 (100 %)	0 diff (100 %id)
CB214980	normal endometrium, late proliferativephase, cycle day 13, uterus	.j	279 to 775	1 to 497	exact	tiling clone,		497/497 (100 %)	0 diff (100 %id)
CN266354	embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7	.k	1 to 498	1 to 498	exact	tiling clone,		498/498 (100 %)	0 diff (100 %id)
DQ323888		.l	1 to 685	1 to 684	exact	tiling clone, AAA		684/684 (100 %)	1 diff (99.9 %id)
AW371105	breast	Gene MDK, variant not shown					This clone was ignored
BG987929	head_neck	Gene MDK, variant not shown					This clone was ignored
CN266433	embryonic stem cells, DMSO-treated H9 cellline	Gene MDK, variant not shown					Suspected internal deletion, this clone was ignored
CN278543	embryonic stem cells, DMSO-treated H9 cellline	Gene MDK, variant not shown					Suspected internal deletion, this clone was ignored
DQ323889		Gene MDK, variant not shown				AAA	Suspected internal deletion, this clone was ignored
DQ323890		Gene MDK, variant not shown				AAA	Suspected internal deletion, this clone was ignored
BE612522	adenocarcinoma, ovary	Gene MDK, variant not shown					Suspected internal deletion, this clone was ignored
BP371892	umbilical cord	Gene MDK, variant not shown				AAA	Suspected internal deletion, this clone was ignored
BP374695	umbilical cord	Gene MDK, variant not shown					Suspected internal deletion, this clone was ignored